Stifel analyst Rick Wise raised the firm’s price target on Edwards Lifesciences (EW) to $105 from $100 and keeps a Buy rating on the shares. The firm, which argues that the 2026 setup is constructive for large-cap MedTech following 2025 pressures, adjusted targets among its coverage and highlights Boston Scientific (BSX), Edwards, and Solventum (SOLV) as its three top ideas entering the year.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $94 from $92 at Evercore ISI
- Edwards Lifesciences receives FDA approval for SAPIEN M3 mitral valve system
- Edwards Lifesciences Advances Smart Surgery Monitoring With Completed SMART TRENDS Study
- Edwards Lifesciences upgraded to Overweight from Neutral at JPMorgan
- Edwards Lifesciences: Buy Rating on Structural Heart Leadership, Accelerating TAVR/TMTT Growth, and Durable Double‑Digit Upside